Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-421 Monotherapy Substitution for ART in HIV-1
NCT03149211Phase 3Withdrawn
- Sponsor
- United BioPharma
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of semzuvolimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by United BioPharma. Planned start Apr 2025; status: withdrawn.
02
Drugs
semzuvolimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03149211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149211.